全文获取类型
收费全文 | 35202篇 |
免费 | 1922篇 |
国内免费 | 150篇 |
专业分类
耳鼻咽喉 | 375篇 |
儿科学 | 784篇 |
妇产科学 | 601篇 |
基础医学 | 6584篇 |
口腔科学 | 758篇 |
临床医学 | 2810篇 |
内科学 | 6600篇 |
皮肤病学 | 1060篇 |
神经病学 | 3643篇 |
特种医学 | 1486篇 |
外科学 | 4873篇 |
综合类 | 175篇 |
一般理论 | 16篇 |
预防医学 | 1819篇 |
眼科学 | 835篇 |
药学 | 2463篇 |
中国医学 | 24篇 |
肿瘤学 | 2368篇 |
出版年
2022年 | 172篇 |
2021年 | 401篇 |
2020年 | 304篇 |
2019年 | 526篇 |
2018年 | 622篇 |
2017年 | 464篇 |
2016年 | 603篇 |
2015年 | 696篇 |
2014年 | 848篇 |
2013年 | 1239篇 |
2012年 | 1746篇 |
2011年 | 1869篇 |
2010年 | 1234篇 |
2009年 | 1190篇 |
2008年 | 1973篇 |
2007年 | 2024篇 |
2006年 | 1912篇 |
2005年 | 2024篇 |
2004年 | 1893篇 |
2003年 | 1837篇 |
2002年 | 1919篇 |
2001年 | 414篇 |
2000年 | 332篇 |
1999年 | 442篇 |
1998年 | 520篇 |
1997年 | 428篇 |
1996年 | 379篇 |
1995年 | 350篇 |
1994年 | 302篇 |
1993年 | 268篇 |
1992年 | 246篇 |
1991年 | 256篇 |
1990年 | 209篇 |
1989年 | 197篇 |
1988年 | 201篇 |
1987年 | 162篇 |
1986年 | 152篇 |
1985年 | 182篇 |
1984年 | 203篇 |
1983年 | 179篇 |
1982年 | 216篇 |
1981年 | 178篇 |
1978年 | 154篇 |
1933年 | 170篇 |
1932年 | 180篇 |
1931年 | 168篇 |
1930年 | 169篇 |
1929年 | 148篇 |
1928年 | 163篇 |
1926年 | 158篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
Tranexamic acid has been advocated for patients with severe bleeding tendency due to thrombocytopenia not responding to platelet transfusions. Macroscopic haematuria is a well-known contraindication for its use in such patients. We present three clinical cases with microscopic haematuria, in whom tranexamic acid caused problems of clot formation in the urinary tract, indicating that microscopic haematuria should also be considered as a contraindication for tranexamic acid. 相似文献
72.
Hans E. Grossniklaus 《American journal of ophthalmology》2005,139(1):220
73.
74.
The duration of response to treatment with alefacept has been assessed in patients with moderate to severe chronic plaque psoriasis who responded to alefacept therapy in phase 2 and phase 3 clinical studies. In a phase 2 trial, duration of response was based on time to retreatment with alefacept. In two phase 3 studies, the more objective measure of maintenance of a ≥50% reduction from baseline Psoriasis Area and Severity Index (PASI 50) was used. Two patient subsets were analyzed: (1) those who achieved a PASI 75 at any time during the trials and (2) those who achieved a Physician Global Assessment of “clear” or “almost clear” at any time during the trials. Regardless of the criterion used or the route of alefacept administration (intravenous or intramuscular), the median duration of response to alefacept therapy ranged from 7 to 10 months across the three studies. Alefacept is a remittive therapy for psoriasis. 相似文献
75.
Eduardo M. B. Tinoco Ståle P. Lyngstadaas Hans R. Preus Per Gjermo 《Journal of clinical periodontology》1997,24(12):937-944
Abstract Immunological data have been suggested to be a potential tool in the diagnosis, classification and monitoring of periodontal diseases. However, the role of circulating antibodies in periodontal patients is poorly understood. Patients suffering from localized juvenile periodontitis (LJP) are often reported to show high titers of serum IgG antibodies against Aetinobaeillus actinomycetemcomitans (A. actinomycetemcotnitans), but several affected patients do not. Most studies use well-known reference strains of the bacterium for testing against the patients' sera. The aim of the present investigation was to study the relationship between serum IgG antibody levels to autologous A. actinomycetemcomitans strains and clinical attachment loss (CAL). In addition, we wanted to assess the patients’serum titers against 4 well-known reference strains of the bacterium as well as their general potential immunoglobulin response. Intravenous blood samples were taken from 23 LJP patients and 10 healthy individuals, and autologous A. actinomycetemcomitans strains were cultured from 18 of the L.JP patients. CAL was measured at 4 different sites around ail present teeth and assessed as a % of teeth with at least 1 site moderately ≥2<5 mm) or severely (≥5 mm) involved. An enzyme-linked immunosorbent assay (ELISA) was performed to evaluate the serum titers of IgG antibodies to A. actinomycetemcomitans antigens. No significant correlation was found between serum IgG antibody titers to autologous strains and CAL. However, there was a trend that low responders had more moderately affected teeth than had high responders and patients with undetectable A. actinomycetemcomitans levels, which is in agreement with a hypothetically protective role of the antibodies. The total counts of immunoglobulin assessed in all participants showed that the predominant class was IgG and the reference group displayed significantly less (p<0.05) IgG and IgG1 counts than the LJP patients. Both the reaction pattern against reference and autologous strains varied widely. We conclude that the specific antibody response against A. actinomycetemcomitans shows a weak correlation to clinical attachment levels in LJP patients. 相似文献
76.
Internal fixation of dorsolumbar spinal fractures can be accomplished by dorsal plating or internal fixator. So far, the technique of transpedicular grafting has been applied to fill the vertebral body with cancellous bone. In this paper, we present a new technique of extended transpedicular bone grafting to fill the intervertebral space also. By this means, the disadvantage of secondary loss of height after removal of the metal implants can be prevented. 相似文献
77.
78.
Gregory E Demas Randy J Nelson Bruce K Krueger Paul J Yarowsky 《Behavioural brain research》1998,90(2):199-201
To evaluate the cognitive phenotype of the segmental trisomy 16 (Ts65Dn) mouse, a model of Down Syndrome (DS, trisomy 21), we assessed spatial working and reference memory using a 12-arm radial maze (RAM). Ts65Dn mice made a greater number of reference memory errors across trials compared to control mice. Both genotypes showed improvement across trials, although improvement was slower in Ts65Dn mice. Ts65Dn mice also made a greater number of working memory errors on the RAM, and in contrast to control mice, did not improve across trials, always performing at near-chance levels. These results provide evidence for both spatial working and reference memory deficits in Ts65Dn mice, characteristics of cognitive dysfunction. 相似文献
79.
Azra Raza Harvey D. Preisler Ya Qin Li Richard A. Larson Jack Goldberg George Browman John Bennett Hans Grunwald Ralph Vogler Cathi Kukla 《American journal of hematology》1993,42(4):359-366
A pilot study was conducted of the biological characteristics of the leukemia cells of newly diagnosed patients with poor prognosis acute myelogenous leukemia (AML). This study included measurements of the pretherapy proliferative rate of the leukemia cells in vivo, assessment of differentiation in vivo during remission induction therapy, and the level of expression of the fms, myc, and IL1β genes in pretherapy leukemia cells. Short cell cycle times were characteristic of the best prognostic category and were associated with a rapid reduction in marrow leukemia cells in cytosine arabinoside (araC)-sensitive patients. Expression of c-fms was associated with rapid reduction in marrow leukemia cells during araC therapy and with a successful treatment outcome. Expression of the IL1β gene was associated with short remissions. These studies suggest that when compared to newly diagnosed standard prognosis AML, the leukemia of poor prognosis patients is more likely to exhibit long cell cycle times, low levels of fms expression, and is less likely to be associated with myeloid differentiation during remission induction therapy. © 1993 Wiley-Liss, Inc. 相似文献
80.
Michael Fromm Wolfgang E. Berdel Hans D. Schick Susanne Danhauser-Riedl Ulrich Fink Wolfgang Remy Anneliese Reichert Anke Ankele Heinz W. Präuer Jörg R. Siewert Johann Rastetter 《Investigational new drugs》1988,6(3):189-194
Summary Carbetimer, a new synthetic low molecular weight polyelectrolyte with a novel structure displayed antitumor activiy in a number of animal tumor model systems and in vitro investigations. Based on these findings it was brought to a phase I clinical trial in patients with advanced malignant disease after failure of conventional treatment or with no conventional treatment available. Forty-eight patients received 98 courses. The schedule was a one hour i.v. infusion every four weeks. The starting dose was 180 mg/m2 and dose escalation was performed according to a modified Fibonacci formula up to 16,690 mg/m2. At least three patients were treated at each dose level and each patient was eligible to receive repeat courses at the same dose, until progressive disease or dose-limiting toxicity intervened. No hematological toxicity was encountered. Some adverse effects such as reversible proteinuria, hypercalcaemia, pain at infusion site, nausea and vomiting and fatigue were seen partly in a dose-related manner but did not represent the maximum tolerated dose (MTD). The limiting toxicity at the highest dose level of 16,690 mg/m2 consisted of ocular symptoms (light flashes) accompanied by a modest decrease of blood pressure and nausea or vomiting during a one hour infusion. 16,690 mg/m2/1 hour was considered the MTD. There were four deaths on study, all considered diseaserelated. Fourteen patients had stable disease for more than two courses, which, however, could also be explained by the natural course of disease. No clear-cut antitumor responses were noted in our study center.The recommended dose for phase II trials derived from our results is 12,550 mg/m2/2 hours. However, with regard to experiences in other phase I studies, the subsequent phase II studies will be performed with a dose of 6,500 mg/m2. 相似文献